RISK OF PHARMACOKINETIC DRUG-DRUG INTERACTIONS WITH NOVEL DRUGS APPROVED BY THE US FDA IN 2022: A DETAILED REVIEW OF DDI DATA FROM NDA DOCUMENTATION

被引：0
|
作者：
Yu, Jingjing [1 ]
Wang, Yan [1 ]
Ragueneau-Majlessi, Isabelle [1 ]
机构：
[1] Certara, Princeton, NJ USA
来源：
DRUG METABOLISM AND PHARMACOKINETICS | 2024年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P69
引用
收藏
页数：2
相关论文
共 34 条
  • [31] Drug-drug interactions via mechanism-based cytochrome P450 inactivation:: Points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation
    Venkatakrishnan, Karthik
    Obach, R. Scott
    CURRENT DRUG METABOLISM, 2007, 8 (05) : 449 - 462
  • [32] Drug Repositioning via Graph Neural Networks: Identifying Novel JAK2 Inhibitors from FDA-Approved Drugs through Molecular Docking and Biological Validation
    Yasir, Muhammad
    Park, Jinyoung
    Han, Eun-Taek
    Park, Won Sun
    Han, Jin-Hee
    Chun, Wanjoo
    MOLECULES, 2024, 29 (06):
  • [33] How precise is quantitative prediction of pharmacokinetic effects due to drug-drug interactions and genotype from in vitro data? A comprehensive analysis on the example CYP2D6 and CYP2C19 substrates
    Duecker, Christof
    Brockmoeller, Juergen
    PHARMACOLOGY & THERAPEUTICS, 2021, 217
  • [34] A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020
    Sivanandy, Palanisamy
    Jun, Pee Hui
    Man, Lai Weng
    Wei, Ng Sin
    Mun, Nicole Foo Kar
    Yii, Celestine Ang Jia
    Ying, Charissa Cheah Xiao
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2022, 15 (03) : 285 - 292
1234